Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
Las Vegas Sun

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.: Vertex to Acquire Crinetics Pharmaceuticals

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.